2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The association between lower urinary tract symptoms secondary to benign prostatic hyperplasia and multimorbidity among Chinese middle-aged and elderly males: evidence based on propensity score matching

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          With the aging population, patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) often face multiple chronic conditions (multimorbidity), significantly impacting their quality of life. This study aims to determine the relationship between LUTS/BPH, multimorbidity, and various chronic diseases in middle-aged and elderly Chinese populations.

          Methods

          This cross-sectional study utilizes data from the China Health and Retirement Longitudinal Study (CHARLS), involving 6,645 residents aged 45 and above. Data on 14 chronic diseases were collected, with multimorbidity defined based on the presence of 2–5 chronic conditions. The number of chronic conditions was further categorized into five groups. Propensity score matching (PSM) was used to control for 11 confounding factors. Linear regression was employed to analyze the relationship between LUTS/BPH and the number of chronic conditions in middle-aged and elderly Chinese men before and after PSM. Both univariate and multivariate logistic regression analyses were used to explore the association between LUTS/BPH and multimorbidity as well as each chronic disease.

          Results

          The prevalence of multimorbidity was significantly higher among middle-aged and elderly individuals with LUTS/BPH compared to those without. Before PSM, LUTS/BPH was positively correlated with the number of chronic diseases (β=0.175, P<0.001), and the risk of multimorbidity significantly increased, showing a dose-response relationship. The risk of having at least two chronic diseases in patients with LUTS/BPH was 2.39 times higher than in those without LUTS/BPH [odds ratio (OR) =2.39, 95% confidence interval (CI): 2.04–2.80], and the risk of having five chronic diseases was 3.97 times higher (OR =3.97, 95% CI: 3.14–4.99). After PSM, 819 pairs were successfully matched. The positive correlation between LUTS/BPH and multimorbidity still existed, with the risks of having at least two and five chronic diseases being 2.37 times (OR =2.37, 95% CI: 1.94–2.90) and 3.69 times (OR =3.69, 95% CI: 2.62–5.29) higher, respectively. Among them, the risk of emotional/nervous/psychiatric problems was the highest in LUTS/BPH patients (OR =6.58, 95% CI: 2.22–28.13), while the risk of arthritis/rheumatism was the lowest (OR =1.60, 95% CI: 1.30–1.98).

          Conclusions

          In the Chinese population, LUTS/BPH is closely associated with multimorbidity and each of the 14 chronic diseases examined, with a dose-response relationship based on the number of chronic diseases defined within multimorbidity. It is imperative to incorporate LUTS/BPH into multimorbidity research and management. We recommend that clinicians and policymakers consider the increased risk of multimorbidity and various chronic diseases among male LUTS/BPH patients.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: not found
          • Article: not found

          Multimorbidity

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis

            Background Knowing the prevalence of multimorbidity among adults across continents is a crucial piece of information for achieving Sustainable Development Goal 3.4, which calls for reducing premature death due to non-communicable diseases. A high prevalence of multimorbidity indicates high mortality and increased healthcare utilization. We aimed to understand the prevalence of multimorbidity across WHO geographic regions among adults. Methods We performed a systematic review and meta-analysis of surveys designed to estimate the prevalence of multimorbidity among adults in community settings. We searched PubMed, ScienceDirect, Embase and Google Scholar databases for studies published between January 1, 2000, and December 31, 2021. The random-effects model estimated the pooled proportion of multimorbidity in adults. Heterogeneity was quantified using I 2 statistics. We performed subgroup analyses and sensitivity analyses based on continents, age, gender, multimorbidity definition, study periods and sample size. The study protocol was registered with PROSPERO (CRD42020150945). Findings We analyzed data from 126 peer-reviewed studies that included nearly 15.4 million people (32.1% were male) with a weighted mean age of 56.94 years (standard deviation of 10.84 years) from 54 countries around the world. The overall global prevalence of multimorbidity was 37.2% (95% CI = 34.9–39.4%). South America (45.7%, 95% CI = 39.0–52.5) had the highest prevalence of multimorbidity, followed by North America (43.1%, 95% CI = 32.3–53.8%), Europe (39.2%, 95% CI = 33.2–45.2%), and Asia (35%, 95% CI = 31.4–38.5%). The subgroup study highlights that multimorbidity is more prevalent in females (39.4%, 95% CI = 36.4–42.4%) than males (32.8%, 95% CI = 30.0–35.6%). More than half of the adult population worldwide above 60 years of age had multimorbid conditions (51.0%, 95% CI = 44.1–58.0%). Multimorbidity has become increasingly prevalent in the last two decades, while the prevalence appears to have stayed stable in the recent decade among adults globally. Interpretation The multimorbidity patterns by geographic regions, time, age, and gender suggest noticeable demographic and regional differences in the burden of multimorbidity. According to insights about prevalence among adults, priority is required for effective and integrative interventions for older adults from South America, Europe, and North America. A high prevalence of multimorbidity among adults from South America suggests immediate interventions are needed to reduce the burden of morbidity. Furthermore, the high prevalence trend in the last two decades indicates that the global burden of multimorbidity continues at the same pace. The low prevalence in Africa suggests that there may be many undiagnosed chronic illness patients in Africa. Funding None.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Examining variation in the measurement of multimorbidity in research: a systematic review of 566 studies.

              A systematic understanding of how multimorbidity has been constructed and measured is unavailable. This review aimed to examine the definition and measurement of multimorbidity in peer-reviewed studies internationally.
                Bookmark

                Author and article information

                Journal
                Transl Androl Urol
                Transl Androl Urol
                TAU
                Translational Andrology and Urology
                AME Publishing Company
                2223-4683
                2223-4691
                26 September 2024
                30 September 2024
                : 13
                : 9
                : 1932-1945
                Affiliations
                [1 ]Department of Urology, Linyi Maternity and Child Health Care Hospital, Linyi , China;
                [2 ]Department of Clinical Medicine, Shandong Medical College, Linyi , China
                Author notes

                Contributions: (I) Conception and design: C Liu, S Cao; (II) Administrative support: Y Xia; (III) Provision of study materials or patients: H Guan; (IV) Collection and assembly of data: C Liu; (V) Data analysis and interpretation: F Wang, C Liu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

                Correspondence to: Chuanfeng Liu, MD. Department of Urology, Linyi Maternity and Child Health Care Hospital, No. 6 Jvcai Road, Lanshan District, Linyi 276000, China. Email: wdmxq1314@ 123456qq.com .
                Article
                tau-13-09-1932
                10.21037/tau-24-268
                11491211
                39434733
                2f6364e2-a683-4922-8556-044eeb679c74
                2024 AME Publishing Company. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

                History
                : 03 June 2024
                : 08 September 2024
                Categories
                Original Article

                multimorbidity,chronic disease,benign prostatic hyperplasia (bph),propensity score matching (psm)

                Comments

                Comment on this article